Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  International Journal of Clinical and Experimental Medicine

• Publication date

  2014-10-15

• Fields of study

  Medicine

• Identifiers
  PMID 25419366PMCID PMC4238547
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• mTOR inhibitors in the treatment of breast cancer.

  2013cited by this paper
• Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

  2013cited by this paper
• Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  2013cited by this paper
• Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

  2013cited by this paper
• Everolimus in hormone receptor-positive advanced breast cancer: targeting receptor-based mechanisms of resistance.

  2013cited by this paper
• New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus

  2013cited by this paper
• Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

  2013cited by this paper
• mTOR signaling in growth control and disease.

  2012cited by this paper
• Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.

  2012cited by this paper
• Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials.

  2012cited by this paper
• Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

  2012cited by this paper
• Breast Cancer: Blocking both driver and escape pathways improves outcomes

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• mTOR inhibitors in breast cancer: a systematic review.

  2012influential reference
• Reversing hormone resistance: have we found the golden key?

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.

  2012influential reference
• Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

  2011cited by this paper
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

  2011cited by this paper
• “Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?

  2011cited by this paper
• Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.

  2011cited by this paper
• Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

  2011cited by this paper
• Reversal of Tamoxifen Resistance (Hormone Resistance) by Addition of Sirolimus (mTOR Inhibitor) in Metastatic Breast Cancer

  2011cited by this paper
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

  2009cited by this paper
• mTOR signalling in human cancer.

  2007cited by this paper
• TOR signaling in growth and metabolism.

  2006cited by this paper
• Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses

  2001cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper

• Ilex latifolia Improves the Anti-Tumor Effectiveness of Rapamycin Against Breast Cancer In Vitro and In Vivo

  2025cites this paper
• ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.

  2025cites this paper
• Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.

  2018cites this paper
• Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification

  2017cites this paper
• Traditional Chinese medicine Danggui Buxue Tang inhibits colorectal cancer growth through induction of autophagic cell death

  2017cites this paper
• Single Nucleotide Polymorphisms and Osteoarthritis

  2016cites this paper
• The therapeutic potential of mTOR inhibitors in breast cancer.

  2016cites this paper
• Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

  2015cites this paper
• Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis

  2015cites this paper